DT120

Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yetListed from FDA or ClinicalTrials.gov records; an editor has not checked it yet.

Definium Therapeutics, Inc. DFTX · Generalized Anxiety Disorder; Major Depressive Disorder

Key figures

  • Next catalyst

    None scheduled

    Only dates with a source are listed

  • Phase

    Phase 3

    Not recorded

  • Linked trials

    4

    From ClinicalTrials.gov

  • Latest FDA action

    None on record

    From Drugs@FDA

Recalls, shortages, patents and EU status at a glance

Key information

Indications
Generalized Anxiety Disorder; Major Depressive Disorder Source: Conditions from ClinicalTrials.gov (opens in a new tab)
Designations
None recorded
Next catalyst
None scheduled

Development timeline

  1. Preclinical Completed
  2. Phase 1 Completed
  3. Phase 2 Completed
  4. Phase 3 Current stageFirst trial start 11 Dec 20244 linked trials
  5. Filed Not yet
  6. Approved Not yet

Overview

Mechanism
Not recorded
Route
Not recorded
Modality
Not recorded
Specialties
Not recorded

Overview text is written by HealthTrade editors.

Key dates

No catalysts yet. Editors add each date together with its source.

FDA designations

No FDA designations are on record for DT120. Editors add each one with its source.

Filed application

No filed application is on record for DT120. Approvals are listed under FDA actions.

FDA advisory committees

No FDA advisory committee meetings are on record for DT120.

Clinical trials

Trials linked to DT120
TrialTitlePhaseStatusEnrollmentPrimary completionResults posted
NCT07592689ClinicalTrials.gov record for NCT07592689 (opens in a new tab)A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Phase 3Recruiting165 (estimated)Sep 2027 (estimated) No
NCT06941844ClinicalTrials.gov record for NCT06941844 (opens in a new tab)A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)Phase 3Active, not recruiting149 (actual)20 May 2026 (actual) No
NCT06809595ClinicalTrials.gov record for NCT06809595 (opens in a new tab)A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Phase 3Active, not recruiting245 (actual)13 Aug 2026 (actual) No

Publications listing NCT06809595 (1), newest first

  1. Psychedelic medicine: mechanisms, evidence, and translation to practice.

    BMJ (Clinical research ed.) · 2026 Feb 23

Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.

NCT06741228ClinicalTrials.gov record for NCT06741228 (opens in a new tab)A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Phase 3Active, not recruiting214 (actual)15 Jul 2026 (actual) No

Publications listing NCT06741228 (1), newest first

  1. Psychedelic medicine: mechanisms, evidence, and translation to practice.

    BMJ (Clinical research ed.) · 2026 Feb 23

Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.

Trial quality

About CT-VCA

Loading trial quality…

FDA actions

No FDA approvals on record for this drug.

FDA recalls load here.

FDA drug shortages load here.

Orange Book patents load here.

FAERS adverse event counts load here.

Papers and preprints load here.

Community discussion loads here.

EU status (EMA)

EMA's medicines data lists no human medicine with the same active substance as DT120.

Source: European Medicines Agency (EMA), medicines data download.

Related news

No recent headlines mention this drug.

Sources

Record updated .

Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.